Opus Genetics' Gene Therapy Shows Early Promise in Rare Retinal Disease Trial
Event summary
- Opus Genetics reported positive 3- and 6-month data from Cohort 1 of its Phase 1/2 trial for OPGx-BEST1, showing clinically meaningful improvements in visual function and retinal structure in all five participants.
- The FDA aligned on a potential pivotal endpoint of ≥3 decibels microperimetry improvement combined with patient-reported outcomes.
- Cohort 2 dosing is expected to complete in Q4 2026, with topline 3-month data anticipated in Q2 2027.
- New epidemiology research estimates 23,600 symptomatic BEST1 patients in the U.S. and 45,400 globally, suggesting a larger addressable market than previously thought.
The big picture
Opus Genetics' positive Phase 1/2 data for OPGx-BEST1 marks a critical milestone in the development of gene therapies for BEST1-related retinal diseases, a space with no approved treatments. The FDA's alignment on pivotal endpoints and the over-enrollment of Cohort 2 suggest strong momentum, but the company's success will hinge on sustaining these results in larger, controlled trials. The broader implications for rare disease gene therapy development could be significant if OPGx-BEST1 proves effective, potentially setting a precedent for similar treatments.
What we're watching
- Regulatory Pathway
- Whether the FDA's alignment on pivotal endpoints will accelerate OPGx-BEST1's path to Phase 3 trials and potential approval.
- Clinical Efficacy
- The extent to which Cohort 2 data will reinforce or challenge the positive findings from Cohort 1, particularly at the higher dose.
- Market Potential
- How the expanded patient population estimates will impact Opus Genetics' strategic positioning and valuation.